Zurzuvae's Potential | Explore Sage Therapeutics' launch of Zurzuvae for postpartum depression, with favorable metrics despite slower market development and a U.S. peak sales estimate of $350-400 million. |
Pipeline Challenges | Delve into Sage's high-stakes pipeline, focusing on Dalzanemdor's upcoming Phase II readouts for Huntington's and Alzheimer's diseases, crucial for the company's future prospects. |
Financial Hurdles | Learn about Sage's financial outlook, projecting revenue growth to $524 million by 2026, but facing profitability challenges due to high expenses and uncertain pipeline outcomes. |
Market Positioning | Analysts set price targets ranging from $10 to $12, reflecting a balance between Sage's potential in CNS disorders and the risks associated with drug development and commercialization. |
Chỉ số cần so sánh | SAGE | Lĩnh vực Ngành- Số liệu trung bình từ một nhóm lớn các công ty Y Tế liên quan thuộc ngành | Mối quan hệ Mối quan hệSAGECông TyLĩnh vực | |
---|---|---|---|---|
Tỉ số P/E | −1.5x | −1.8x | −0.5x | |
Tỷ Lệ PEG | −0.05 | −0.01 | 0.00 | |
Giá/G.Trị Sổ Sách | 1.3x | 2.2x | 2.6x | |
Giá / Doanh Số 12T | 11.5x | 64.9x | 3.2x | |
Tăng (Mục Tiêu của Nhà Phân Tích) | −2.1% | 309.8% | 43.8% | |
Giá Trị Hợp Lý Tăng | Mở Khóa | 34.6% | 8.1% | Mở Khóa |